Findings from a new study – the largest of its kind – indicate that heavy alcohol consumption is the most significant risk factor for the development of dementia.
Researchers from Queensland University of Technology have identified a drug that could reverse the damaging effects of heavy alcohol consumption on neurogenesis.
Signature patterns of electrical activity in the brain may predict impulsive behaviors, suggesting deep brain stimulation could hold potential as a treatment for several mental disorders.
Key research from the conference highlights opioid addiction research.
Researchers have shown how analysis of tweets from Twitter can match established metrics of opioid misuse in the USA.
Promising pharmacogenetic targets for treating alcohol use disorder: evidence from preclinical models
This review explores promising novel genetic variants derived from preclinical models of alcohol consumption and dependence, and identifies novel pharmacogenetic targets that facilitate therapeutic intervention for the treatment of alcohol use disorder.
Andie Asimes discusses her work on binge alcohol consumption in adolescence and how the epigenetic consequences of this can lead to a higher predisposition for mental health disorders in offspring.
Webinar Q&A follow-up: Manipulation of Abuse Deterrent Formulations at the Clinical Pharmacology Unit
Read the Q&A transcript and responses to the unanswered questions from our webinar on ‘Manipulation of Abuse Deterrent Formulations at the Clinical Pharmacology Unit’.
Neural circuitry changes in the brain induced by chronic cocaine use can be reduced through microglial release of TNF-α, providing hope for the development of addiction-suppressing therapies.
Probuphine, the first buprenorphine implant designed for the maintenance treatment of opioid dependence has been approved by the U.S. FDA.